As shown in Table 3, with the exception of lixisenatide (n = 14), which was not included because the number of AEs was insufficient for analysis, differential analyses of gender, age, and body weight were performed between severe and non-severe cases in patients with AEs of metabolism and nutrition disorders who were treated with the remaining six GLP-1 RAs. The gene discussed is GLP1R; the disease is nutritional disorder.